Skip to main
  1. Stocks
  2. Prenetics Global Ltd
  3. Forecast
PRE

PRE Stock Forecast & Price Target

PRE Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Prenetics Global is supported by a rapidly scaling IM8 franchise that has reached about $200 million in ARR as of May 31 and generated preliminary record revenue of about $17 million in June, while 1Q26 total revenue from continuing operations rose 333% year over year to $36 million. Its fundamentals are strengthened by a $1 billion growth financing that funds up to 70% of IM8 marketing spend without dilution, plus an estimated $139.7 million in cash and investments, easing balance-sheet risk and improving capital efficiency. The brand also benefits from clinically validated, NSF Certified for Sport products, a 3:1 LTV/CAC, and quarterly subscriptions that have lifted AOV to $240 and accelerated cash collection, supporting FY26 revenue guidance of $210-$220 million and expected FY27 revenue above $400 million.

Bears say

Prenetics Global is a high-risk consumer wellness company whose growth depends on turning one-time buyers into recurring subscribers, yet its business remains exposed to churn, changing consumer preferences, and intense competition in the nutritional supplement market. Its IM8 model also carries heavy operating pressure from sales and marketing, global freight and fulfillment costs, and potentially rising customer acquisition costs, even as only about 80% of all new IM8 orders as of December 31, 2025 were subscription-based. In addition, the lack of FDA approval for dietary supplements, geopolitical and supply-chain exposure tied to Hong Kong and China, and concentrated control by Chairman and CEO Danny Yeung with more than 50% voting power create regulatory, governance, and execution risks that could limit long-term profitability.

PRE has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Prenetics Global Ltd and is not a guaranteed prediction by Public.com or investment advice.

PRE Analyst Forecast & Price Prediction

Get the latest PRE stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in PRE

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Prenetics Global Ltd (PRE) Forecast

Analysts have given PRE a Strong Buy based on their latest research and market trends.

According to 6 analysts, PRE has a Strong Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $39.17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $39.17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Prenetics Global Ltd (PRE)


PRE Analyst Forecast & Price Prediction

Get the latest PRE stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in PRE

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover PRE stock data and trends